Browsing Tag
Tucatinib
5 posts
Why Lunit’s AACR 2026 showcase could reshape how investors value AI-driven precision oncology platforms like KRX: 328130
Lunit’s AACR 2026 studies reveal how its cancer AI platform is moving beyond pathology into biomarker strategy. Read what this means for KRX: 328130.
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.
Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration…
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two…
Seattle Genetics to acquire Cascadian Therapeutics for $614m to bolster oncology portfolio
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million,…